Covered recipient · General Payments record
KENNETH HERSHON
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$75,304.24
- Reported across 254 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $352.44 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $108.29 | 5 |
| ABBVIE INC. | $51.50 | 3 |
| Lilly USA, LLC | $50.96 | 2 |
| Xeris Pharmaceuticals, Inc. | $39.65 | 2 |
| SANOFI-AVENTIS U.S. LLC | $28.91 | 1 |
| Abbott Laboratories | $23.88 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $20.49 | 1 |
| Amgen Inc. | $15.61 | 1 |
| Antares Pharma, Inc. | $13.15 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.88 | 03/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124925039 | CMS |
| ABBVIE INC. | $19.12 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103912565 | CMS |
| ABBVIE INC. | $15.41 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103912567 | CMS |
| ABBVIE INC. | $16.97 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103912569 | CMS |
| Amgen Inc. | $15.61 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111598760 | CMS |
| Antares Pharma, Inc. | $13.15 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146463248 | CMS |
| Lilly USA, LLC | $23.44 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135077377 | CMS |
| Lilly USA, LLC | $27.52 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135130082 | CMS |
| Novartis Pharmaceuticals Corporation | $20.49 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086785891 | CMS |
| Novo Nordisk Inc | $20.61 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097588932 | CMS |
| Novo Nordisk Inc | $23.95 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097530730 | CMS |
| Novo Nordisk Inc | $16.92 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096598066 | CMS |
| Novo Nordisk Inc | $16.86 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096986218 | CMS |
| Novo Nordisk Inc | $29.95 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097333096 | CMS |
| SANOFI-AVENTIS U.S. LLC | $28.91 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139659424 | CMS |
| Xeris Pharmaceuticals, Inc. | $16.36 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144601487 | CMS |
| Xeris Pharmaceuticals, Inc. | $23.29 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144601489 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.